Literature DB >> 28304383

Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.

D Călugăru1, M Călugăru1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28304383      PMCID： PMC5519262          DOI： 10.1038/eye.2017.12

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

1.  Re: Yeh et al.: Ophthalmic Technology Assessment: therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology (Ophthalmology 2015;122:769-78).

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Ophthalmology       Date:  2015-11       Impact factor: 12.079

2.  Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion.

Authors:  Gabriel Coscas; Albert Augustin; Francesco Bandello; Marc D de Smet; Paolo Lanzetta; Giovanni Staurenghi; Maria Cristina Parravano; Patricia Udaondo; Elad Moisseiev; Gisele Soubrane; Yossi Yatziv; Anat Loewenstein
Journal:  Eur J Ophthalmol       Date:  2013-10-14       Impact factor: 2.597

3.  A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.

Authors:  David G Callanan; Anat Loewenstein; Sunil S Patel; Pascale Massin; Borja Corcóstegui; Xiao-Yan Li; Jenny Jiao; Yehia Hashad; Scott M Whitcup
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-08       Impact factor: 3.117

4.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Authors:  Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio
Journal:  Ophthalmology       Date:  2011-06-29       Impact factor: 12.079

5.  Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.

Authors:  S Nghiem-Buffet; S Baillif; S Regnier; A Skelly; N Yu; A Sodi
Journal:  Eye (Lond)       Date:  2016-12-02       Impact factor: 3.775
  5 in total
  4 in total

1.  Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-25       Impact factor: 3.117

2.  Response to Comment on: Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.

Authors:  S Nghiem-Buffet; S Baillif; S Regnier; A Skelly; N Yu; A Sodi
Journal:  Eye (Lond)       Date:  2017-02-24       Impact factor: 3.775

3.  Safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-02       Impact factor: 3.117

4.  Comparison of intravitreal dexamethasone implant and anti-VEGF drugs in the treatment of retinal vein occlusion-induced oedema: a meta-analysis and systematic review.

Authors:  Shuai Ming; Kunpeng Xie; Mingzhu Yang; Huijuan He; Ya Li; Bo Lei
Journal:  BMJ Open       Date:  2020-06-28       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.